HIV protease inhibitors acutely impair glucose-stimulated insulin release.
about
Drug-induced diabetes mellitusThe role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implicationsHIV infection and cardiovascular diseaseScreening for chronic kidney disease in HIV-infected patients.HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters.Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice.A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity.Insulin resistance and adipokines serum levels in a caucasian cohort of hiv-positive patients undergoing antiretroviral therapy: a cross sectional study.Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages.The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factorsMolecular Mechanisms for Altered Glucose Homeostasis in HIV InfectionLopinavir/Ritonavir Impairs Physical Strength in Association with Reduced Igf1 Expression in Skeletal Muscle of Older Mice.Body composition and metabolic changes in HIV-infected patientsVitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection.Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants.Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.Disorders of glucose metabolism in human immunodeficiency virus-infected patients.HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer modelsAntiretroviral Therapy-induced Insulin Resistance and Oxidative Deoxy Nucleic Acid Damage in Human Immunodeficiency Virus-1 PatientsMolecular mechanisms for insulin resistance in treated HIV-infection.Endoplasmic reticulum stress in diabetes: New insights of clinical relevance.Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients.Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter.Predictors of glycaemic control among HIV-positive veterans with diabetes.Indinavir alters regulators of protein anabolism and catabolism in skeletal muscle.HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats.Diabetes, metabolic syndrome and dyslipidemia in people living with HIV in Africa: re-emerging challenges not to be forgotten.Effectiveness of a bioactive food compound in anthropometric measures of individuals with HIV/AIDS: A nonrandomized trial.Immune reconstitution in ART treated, but not untreated HIV infection, is associated with abnormal beta cell function.Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia.Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase CExamining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy
P2860
Q22306015-1CD9A5D4-5484-4041-9972-B9D7028B4E1CQ24598812-C738B283-C58A-49B0-AE95-DA4DC8A45BECQ27008915-9268A4DC-41C3-4184-A0DD-9A4A94537093Q33639802-9B623692-33F0-4D2D-9036-7F9A61494763Q33729269-804006C0-43FE-4886-BA48-BD83C663519BQ34035275-32A297A5-73C8-4DF8-A7D6-77EB79D2C77CQ34299021-30C92FB9-98AF-4A86-80E0-90F3848A15CFQ34455618-2D5BD945-4F39-4359-B841-B08EEA619908Q34564051-78402F9B-9087-4E63-B56F-41DE841AC191Q35119834-E920D961-5C6B-4ABC-9B17-FA502BC27343Q35188665-260DD6AF-F5B3-4E9F-A524-BA2734C25BA7Q35206635-86D8AD20-052D-40DD-90FA-6EA5B18CA584Q35250665-5D6B12D3-DB8C-4C6A-B863-1CA2695FEC54Q35915493-933B0AD1-D1CD-4366-8F28-8871F948A646Q35949965-B5C32FFE-F18B-4D69-9349-B7DACFB532A5Q36006301-34A68968-D548-4160-9303-B134CBDBAE1CQ36158019-2B356E66-D81A-461B-9DAA-A13763D52F9FQ36899859-18D32A83-DE4B-4548-8A72-2156B48653F4Q37162243-98EE7DA8-CAEF-4FD6-9749-471594522710Q37246875-61515489-44DC-44BD-917C-E1671DC1A40CQ37339069-26FEC43C-FD00-40D0-B0FA-15D0AC937021Q37447923-9AF41996-5A2B-4920-8F96-AEC5FBC732D7Q37721953-AFA488AC-01AC-4221-AD60-CD91A861CA0AQ37887885-32EE1F77-E61C-4E4D-ABF8-5410E486C939Q38056123-78993F6D-B6BD-4AF8-ACD2-7674A6C84975Q38734899-CBAAE5E4-710B-41F1-98D9-BFC23F08DF77Q39670294-29D85897-F992-400E-AF3C-75F6186AAA70Q39881130-9C72F12A-6FFC-4165-8E0C-164170F6852DQ39887434-AA192E50-EBBF-4EF9-BEF8-7E63E5B4CCDBQ42218775-FAD51865-AB15-410C-8A97-447269D5C95BQ42476875-F977B2BB-504F-4357-A94A-B8C80AAA06C0Q44955970-4180ABE6-65F3-4DFC-8419-499B648F7BDBQ45245267-71A711FC-7175-4682-840D-CF85C24BEC53Q46049540-91582ACF-5034-4D05-A9CC-A6A7A42E72D5Q46765257-B591B57B-B9DC-4EDA-8550-D2AFAB1360A8Q50099461-356173F9-AF82-42A4-B04B-D94ED354DB11Q55342018-220453BE-5DBF-499D-A298-1693DE07C2E8Q55363508-ABE23B31-10D0-4907-9938-F06754DEEC14Q56746595-5C624B31-4452-4966-8361-6BD9E719B323Q58549748-E0AD06E3-10C6-4330-A344-1C5E851B055A
P2860
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@ast
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@en
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@nl
type
label
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@ast
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@en
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@nl
prefLabel
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@ast
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@en
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
@nl
P2093
P2860
P1433
P1476
HIV protease inhibitors acutely impair glucose-stimulated insulin release
@en
P2093
Colin G Nichols
Haijun Qiu
Joseph C Koster
Maria S Remedi
P2860
P304
P356
10.2337/DIABETES.52.7.1695
P407
P50
P577
2003-07-01T00:00:00Z